Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...
In the intricate regulation of inflammation, metabolic reprogramming and posttranslational modification (PTM) have emerged as pivotal players, offering new avenues for understanding the fine-tuned ...
In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the “recipe” for the transformation. Researchers at Lund University have now created ...
Researchers have defined a new genetic disease caused by a mutation in the IVNS1ABP gene. The condition marks a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results